{
  "question_stem": {
    "en": "A 67-year-old smoker comes to the office with a 2-week history of decreased vision in his right eye that he describes as \"blurry\" and \"distorted.\" The patient has been having vision problems over the past year, and these have made it more difficult to drive and require that he use a bright light to read the newspaper. He has no history of diabetes mellitus or hypertension. The patient uses an albuterol inhaler for occasional wheezing and shortness of breath. Ophthalmologic examination of the right eye shows a grayish discoloration of the macula with areas of adjacent hemorrhage. Which of the following should be specifically targeted in treatment of this patient's condition?",
    "zh": "一位67岁的吸烟者来到诊所，主诉右眼视力下降2周，他描述为“模糊”和“变形”。患者在过去一年中一直存在视力问题，这使得他难以驾驶，并且需要使用强光阅读报纸。他没有糖尿病或高血压病史。患者使用沙丁胺醇吸入器治疗偶发性喘息和呼吸短促。右眼眼科检查显示黄斑灰白色变色，伴有邻近出血区。以下哪项应特别针对该患者的病情进行治疗？"
  },
  "question": {
    "en": "Which of the following should be specifically targeted in treatment of this patient's condition?",
    "zh": "以下哪项应特别针对该患者的病情进行治疗？"
  },
  "options": {
    "A": {
      "en": "CD20 lymphocyte glycoprotein",
      "zh": "CD20淋巴细胞糖蛋白"
    },
    "B": {
      "en": "Epidermal growth factor receptor",
      "zh": "表皮生长因子受体"
    },
    "C": {
      "en": "Interleukin-2",
      "zh": "白介素-2"
    },
    "D": {
      "en": "Tumor necrosis factor-alpha",
      "zh": "肿瘤坏死因子-α"
    },
    "E": {
      "en": "Vascular endothelial growth factor",
      "zh": "血管内皮生长因子"
    }
  },
  "correct_answer": "E",
  "explanation": {
    "en": "This patient likely has AGE-RELATED MACULAR DEGENERATION (AMD), the leading cause of blindness in industrialized countries. AMD occurs in genetically predisposed individuals as a result of advancing age and environmental factors (eg, smoking) and is classified into dry and wet subtypes. Dry AMD is characterized by GRADUAL vision loss in one or both eyes and can cause difficulty with driving/reading. The condition likely results from chronic oxidative damage to the retinal pigment epithelium and choriocapillaris, leading to subretinal inflammation with abnormal extracellular matrix formation (eg, confluent drusen, basement membrane thickening). These changes appear on funduscopy as subretinal drusen deposits with pigment abnormalities.\n\nProgressive extracellular matrix accumulation can eventually result in retinal hypoxia, which stimulates local VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) production and causes subretinal neovascularization with formation of leaky vessels. This condition is termed WET AMD and presents with ACUTE vision loss (days to weeks) with METAMORPHOPSIA (distortion of straight lines). Funduscopy shows a grayish-green subretinal discoloration with adjacent fluid/hemorrhage.\n\nPatients with dry or wet AMD may benefit from antioxidant vitamins and zinc, and smokers should receive SMOKING CESSATION counseling to prevent disease progression. Wet AMD usually requires specific treatment with VEGF INHIBITORS (eg, ranibizumab, bevacizumab).\n\n(Choice A) Therapy against the CD20 glycoprotein on B cells (eg, the monoclonal antibody rituximab) is used to treat various lymphomas and active rheumatoid arthritis.\n(Choice B) Epidermal growth factor receptor inhibitors (eg, erlotinib, gefitinib) are used to treat advanced non-small cell lung cancer.\n(Choice C) Anti-interleukin-2 therapy is primarily used for immunosuppression in organ transplant patients and in conditions such as graft versus host disease.\n(Choice D) Inhibitors of tumor necrosis factor-alpha are used in many inflammatory autoimmune conditions, such as rheumatoid arthritis, inflammatory bowel disease, and seronegative spondyloarthropathies.\n\nEducational objective: Wet age-related macular degeneration (AMD) is characterized by retinal neovascularization due to increased vascular endothelial growth factor (VEGF) levels. Patients typically have acute vision loss and metamorphopsia with funduscopy showing a grayish-green subretinal membrane and/or subretinal hemorrhage. Treatment includes smoking cessation and VEGF inhibitor therapy (eg, ranibizumab, bevacizumab).",
    "zh": "该患者可能患有年龄相关性黄斑变性 (AMD)，这是工业化国家失明的主要原因。AMD发生在有遗传易感性的人群中，是由于年龄增长和环境因素（例如，吸烟）导致的，分为干性和湿性亚型。干性AMD的特征是单眼或双眼视力逐渐丧失，可能导致驾驶/阅读困难。这种情况可能源于对视网膜色素上皮和脉络膜毛细血管的慢性氧化损伤，导致视网膜下炎症，伴有异常的细胞外基质形成（例如，融合性玻璃疣、基底膜增厚）。这些变化在眼底镜检查中表现为视网膜下玻璃疣沉积物，伴有色素异常。\n\n进行性细胞外基质积累最终可能导致视网膜缺氧，这会刺激局部血管内皮生长因子 (VEGF) 的产生，并导致视网膜下新生血管形成，形成渗漏血管。这种情况被称为湿性AMD，表现为急性视力丧失（几天到几周），伴有变形视 (METAMORPHOPSIA，直线变形)。眼底镜检查显示灰绿色视网膜下变色，伴有邻近的液体/出血。\n\n患有干性或湿性AMD的患者可能受益于抗氧化维生素和锌，吸烟者应接受戒烟咨询以防止疾病进展。湿性AMD通常需要使用VEGF抑制剂（例如，雷珠单抗、贝伐珠单抗）进行特定治疗。\n\n(选项A) 针对B细胞上的CD20糖蛋白的治疗（例如，单克隆抗体利妥昔单抗）用于治疗各种淋巴瘤和活动性类风湿性关节炎。\n(选项B) 表皮生长因子受体抑制剂（例如，厄洛替尼、吉非替尼）用于治疗晚期非小细胞肺癌。\n(选项C) 抗白介素-2治疗主要用于器官移植患者和移植物抗宿主病等情况下的免疫抑制。\n(选项D) 肿瘤坏死因子-α抑制剂用于许多炎症性自身免疫性疾病，如类风湿性关节炎、炎症性肠病和血清阴性脊柱关节病。\n\n教育目标：湿性年龄相关性黄斑变性 (AMD) 的特征是由于血管内皮生长因子 (VEGF) 水平升高引起的视网膜新生血管形成。患者通常有急性视力丧失和变形视，眼底镜检查显示灰绿色视网膜下膜和/或视网膜下出血。治疗包括戒烟和VEGF抑制剂治疗（例如，雷珠单抗、贝伐珠单抗）。"
  },
  "summary": {
    "en": "This question tests the understanding of the pathophysiology and treatment of wet age-related macular degeneration (AMD). It requires identifying the key molecular mediator responsible for neovascularization in AMD and selecting the appropriate therapeutic target.\n\nTo solve this question, one must recognize the clinical presentation of wet AMD, including acute vision loss, metamorphopsia, and funduscopic findings of hemorrhage and discoloration. Understanding that VEGF drives neovascularization in wet AMD is crucial for selecting the correct treatment target, which involves anti-VEGF therapies.",
    "zh": "这个问题考察了对湿性年龄相关性黄斑变性 (AMD) 的病理生理学和治疗的理解。它要求识别导致AMD新生血管形成的关键分子介质，并选择合适的治疗靶点。\n\n为了解决这个问题，必须认识到湿性AMD的临床表现，包括急性视力丧失、变形视以及出血和变色的眼底镜检查结果。了解VEGF驱动湿性AMD的新生血管形成对于选择正确的治疗靶点至关重要，这涉及抗VEGF治疗。"
  },
  "tags": "Age-related macular degeneration; Wet AMD; Vascular endothelial growth factor; Neovascularization; Ophthalmology; Retinal hypoxia; Anti-VEGF therapy; Metamorphopsia; Smoking cessation",
  "category": "Ophthalmology",
  "question_id": "7721",
  "has_exhibits": true,
  "exhibit_count": 3,
  "exhibit_files": [
    "image1.jpg",
    "image2.jpg",
    "image3.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Ophthalmology 23\\7721",
  "extracted_at": "2025-11-05T19:43:18.485164",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 2,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T18:44:56.391655",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}